Ceva Animal Health Acquires Animal-Biotech Company Scout Bio

Ceva Animal Health has acquired Philadelphia-based Scout Bio to achieve cutting-edge therapies for pets. Phot credit: Shutterstock

Posted January 31, 2024

Ceva Animal Health announced it has acquired Philadelphia-based biotech company Scout Bio to achieve a “significant leap,” in innovation for pet therapeutics.

Scout Bio uses gene therapy and technology to address major areas of unmet medical need in companion animal medicine, according to the company’s website. As part of the acquisition Scout Bio CEO Mark Heffernan joined Ceva as Senior Vice President of Biotherapeutics and CEO of Ceva Biotechnology Campus in Philidelphia.

Ceva is the fifth-largest global animal health company and works to produce pharmaceutical products and vaccines for companion animals, livestock, swine and poultry, according to a release.

Earlier in the month Ceva announced the appointment of its new senior vice president for North America, Brad McCollum, who will oversee all activities in the United States and Canada. McCollum brings 25 years of experience in pharmaceuticals and animal health to the American headquarters based in Lenexa.